Verona Pharma Plc develops therapeutics for respiratory diseases, focusing on its investigational inhaled drug, ensifentrine, for chronic obstructive pulmonary disease (COPD). Two additional formulations of ensifentrine are in Phase II development.
Verona Pharma Plc (VRNA) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Verona Pharma Plc's actual EPS was -$0.40, missing the estimate of -$0.30 per share, resulting in a -34.05% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
